Nithyanandam A, Shanmuga Sundaram N, Chandra Mouleswaran V, Lakshmi Narasimhan R


Objective: To study the outcome of thrombolysis in acute ischemic stroke in our institution over one year period.
Methods: A retrospective descriptive study with details taken from cases with acute ischemic stroke who had received IV
thrombolysis with rtPA-alteplase and the details were analysed.
Results: Out of 41 cases, 28 were males and 13 were females. Mean age was 59, The Mean NIHSS score at admission was 11. The Mean time
delay from the onset of symptoms to needle time was 3.5 hours. 22 subjects (53.65%) had achieved primary outcome in this study. 2 (4.87%)
patients had signicant symptomatic intracranial hemorrhage. Out of 8 total deaths, 5 deaths were due to direct neurological cause including 2
signicant bleed. The mean NIHSS at the time of discharge was 9. Among the 33 survived patients 24 (72.72 %) had favorable MRS outcome (0-
2) at the end of 3 months.
Discussion: There was a signicant treatment effect in terms of the primary out come and secondary outcomes along with slightly lesser
hemorrhagic complications were consistent with the case studies in the literature. The pharmacogenomics variations in metabolization of rtPA
should also be considered.
Conclusion: Acute Stroke management should be given priority and due consideration for earlier management. Alteplase signicantly improves
the overall likelihood of a good stroke outcome at 3–6 months. The proportional benet increases with earlier treatment.


Stroke thrombolysis, RTPA, Tissue plasminogen-activator

Full Text:



Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue

plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274(13):1017-1025.

Group NS. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA stroke study group. N Engl J Med. 1995;333(24):


Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274 (13):1017-1025

Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second

European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352 (9136):1245-1251.

Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset.

The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282(21):2019-2026.

Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;


Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomized trial. Lancet Neurol. 2008;7(4):299-309

Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329.

Wahlgren N, Ahmed N, Da´valos A, et al. Thrombolysis with alteplase 3-4.5h after acute ischaemic stroke (SITSISTR): an observational study. Lancet. 2008;372(9646): 1303-1309

Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an update pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695-1703.

Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379(9834):2352-2363.

. Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2014; 7(7):CD000213

Cronin CA, Sheth KN, Zhao X, et al. Adherence to third European cooperative acute stroke study 3- to 4.5-hour exclusions and association with outcome: data from get with the guidelines- stroke. Stroke. 2014;45(9):2745-2749

Thomalla G, Schwark C, Sobesky J. Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis within 6 Hours in MRI-Selected Stroke Patients: Comparison of a German Multicenter Study with the Pooled Data of ATLANTIS, ECASS, and NINDS tPA Trials. Stroke. 2006;37:852-8.

Schellinger PD, Thomalla G, Fiehler J. MRI-Based and CT-Based Thrombolytic Therapy in Acute Stroke Within and Beyond Established Time Windows : An Analysis of 1210 Patients. Stroke. 2007;38:2640-5.

Ogata T, Christensen S, Nagakane Y. The Effects of Alteplase 3 to 6 Hours After Stroke in the Epithet–defuse Combined Dataset Post Hoc Case–Control Study. Stroke. 2013;44:87-93.

Saposnik G, Guzik AK, Reeves M. Stroke Prognostication using Age and NIH Stroke Scale, SPAN-100, Neurol. 2013;80:21-8.


  • There are currently no refbacks.